Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Alfuzosin/voriconazole interaction

Alfuzosin/voriconazole interaction Reactions 1704, p23 - 2 Jun 2018 Blood pressure decreased: case report A 69-year-old man experienced a decrease in blood pressure following concurrent administration of alfuzosin and voriconazole [routes, dosages, duration of treatments to reaction onsets and outcome not stated]. The man had a medical history of acute myeloid leukaemia and urinary disorders. Due to invasive pulmonary aspergillosis he received treatment with voriconazole. He was also receiving treatment with alfuzosin for the urinary disorders for a year. When he visited the regular pharmacist, a drug interaction between alfuzosin and voriconazole was detected. The potent inhibitor of cytochrome (CYP) 3A4 (voriconazole) are contraindicated with the urologic alpha-blocker (alfuzosin). The treatment with voriconazole was initiated during the hospitalisation and a drop in blood pressure was noted. The pharmacist had a discussion with the haematologist, who had prescribed voriconazole to the patient and informed about the contraindication. The man’s treatment with alfuzosin was discontinued and he was treated with tamsulosin for the underlying urinary disorders. Author comment: At most, it is possible to suggest a decrease in the dosage of alpha-blocker when faced with a patient in whom side effects such as dizziness or orthostatic hypotension occur when a potent inhibitor is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Alfuzosin/voriconazole interaction

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Alfuzosin/voriconazole interaction

Abstract

Reactions 1704, p23 - 2 Jun 2018 Blood pressure decreased: case report A 69-year-old man experienced a decrease in blood pressure following concurrent administration of alfuzosin and voriconazole [routes, dosages, duration of treatments to reaction onsets and outcome not stated]. The man had a medical history of acute myeloid leukaemia and urinary disorders. Due to invasive pulmonary aspergillosis he received treatment with voriconazole. He was also receiving treatment with alfuzosin for the...
Loading next page...
 
/lp/springer_journal/alfuzosin-voriconazole-interaction-3FZGUGt030

References (2)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46666-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p23 - 2 Jun 2018 Blood pressure decreased: case report A 69-year-old man experienced a decrease in blood pressure following concurrent administration of alfuzosin and voriconazole [routes, dosages, duration of treatments to reaction onsets and outcome not stated]. The man had a medical history of acute myeloid leukaemia and urinary disorders. Due to invasive pulmonary aspergillosis he received treatment with voriconazole. He was also receiving treatment with alfuzosin for the urinary disorders for a year. When he visited the regular pharmacist, a drug interaction between alfuzosin and voriconazole was detected. The potent inhibitor of cytochrome (CYP) 3A4 (voriconazole) are contraindicated with the urologic alpha-blocker (alfuzosin). The treatment with voriconazole was initiated during the hospitalisation and a drop in blood pressure was noted. The pharmacist had a discussion with the haematologist, who had prescribed voriconazole to the patient and informed about the contraindication. The man’s treatment with alfuzosin was discontinued and he was treated with tamsulosin for the underlying urinary disorders. Author comment: At most, it is possible to suggest a decrease in the dosage of alpha-blocker when faced with a patient in whom side effects such as dizziness or orthostatic hypotension occur when a potent inhibitor is

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.